title: Deferasirox as adjunctive therapy for mucormycosis.
abstract: Mucormycosis can be devastating and, as yet, there are no ideal therapies available. Observations that iron chelation may be a useful adjunct to antifungal treatment encouraged Spellberg et al. (J Antimicrob Chemother 2012; 715-22) to undertake a trial of deferasirox combined with liposomal amphotericin B (AmBisome(®)) as short-term therapy for mucormycosis. The results were disappointing as patients treated with deferasirox had a higher mortality rate at 90 days, leading the authors to conclude that the data did not support a role for initial, adjunctive deferasirox therapy for mucormycosis. We review the issues arising from this study to help decide whether the evidence that now exists supports further studies or represents the end of this line of enquiry.
authors.affiliation: Department of Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. p.donnelly@usa.net
authors.forename: J Peter
authors.initials: JP
authors.lastname: Donnelly
authors.forename: Meir
authors.initials: M
authors.lastname: Lahav
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D000077588:Deferasirox; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008297:Male; D009091:Mucormycosis / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D000935:Antifungal Agents; D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077588:Deferasirox